Shilpa Medicare Ltd. Share Price

Complex generics and CDMO drive growth potential

Shilpa Medicare: Complex generics and CDMO drive growth potential Shilpa Medicare Limited (NSE: SHILPAMED) operates across pharmaceutical formulations, active pharmaceutical ingredients and biotechnology-related businesses. Its opportunities include complex generics, specialty products and contract development and manufacturing. **Why it matters:** Complex formulations and higher-value pharmaceutical products can support better business opportunities, but commercialisation timelines, regulatory approvals and research expenditure can affect returns. **My view:** The key is converting its product pipeline and manufacturing capabilities into consistent commercial revenue. Investors should track whether growth translates into improved operating margins and cash generation, rather than relying solely on pipeline potential. **What to watch:** Regulatory approvals, product launches, formulation revenue, CDMO business growth, operating margins and working-capital requirements. **Stance:** Specialty pharmaceuticals offer long-term potential, but execution, regulatory progress and valuation remain important factors in assessing Shilpa Medicare. Disclosure: I am a SEBI Registered Research Analyst. This content is for educational purposes and is not a recommendation to buy or sell any security.

See More

Shilpa Medicare – Technical Analysis, Support and Resistance

The stock

is in a strong bullish trend on the daily chart. The stock has moved sharply from around ₹600 to above ₹1,000 and continues to form higher highs and higher lows. The latest close is around ₹1064 near its recent high zone. Support & Resistance: Immediate resistance is around ₹1095–1100 near the recent high. A sustained breakout above this zone with strong volume can indicate further continuation. On the downside ₹1030–1040 is the first important support, followed by ₹1000–1010. A deeper correction can find support around ₹950–970. Technical data also places support near ₹1029 and resistance around ₹1070–1093. Short-Term Buyers & Holders View: For short-term buyers, the current move is already extended so chasing after a sharp rally carries higher volatility. Price holding above ₹1030–1040 would keep the bullish structure intact. A breakout and sustained close above ₹1100 can strengthen momentum. Conversely a breakdown below ₹1000 can indicate a deeper short-term correction.

See More

Shilpa Medicare Promoter Group Releases 30 Lakh Shares

Ltd’s promoter group has released the encumbrance on 30,00,000 equity shares, representing 1.5337% of the company’s equity, previously held with Bajaj Finance Limited. The release of encumbrance was disclosed on September 25, 2026, through the company’s regulatory filing. The development indicates that the specified shares are no longer subject to the previously disclosed encumbrance arrangement with Bajaj Finance. Such changes in promoter share encumbrance are monitored by investors as part of the company’s shareholding and financing disclosures. The latest filing provides clarity on the change in the status of the promoter group’s pledged or encumbered shareholding. Investors will continue to track subsequent disclosures for any further changes in promoter holdings or encumbrance levels.

See More

Shilpa Medicare has become a high-growth oncology/specialty

1. Oncology + specialty formulations: Shilpa is expanding from APIs into higher-value finished formulations and complex injectable products. 2. Biologics/biosimilars: The company has several programmes, including nivolumab, pembrolizumab, daratumumab and dupilumab. It also signed an agreement with Orion to develop and supply a nivolumab biosimilar for Europe. 3. New Oeris approval: On September 11, Shilpa received final SEC approval for Oeris, an extended-release ondansetron injection designed to provide up to 120 hours of antiemetic protection for chemotherapy patients. This is an important new-product opportunity in oncology supportive care. 4. CDMO opportunity: Shilpa is increasingly targeting complex molecules such as HPAPIs, peptides, ADCs, PROTACs and oligonucleotides. Its new Shilpa CDMO platform is expected to be formally launched at CPHI Milan in October 2026.

See More

Shilpa Medicare Gets SEC Nod for OERIS™ Launch in India

Shilpa Medicare Ltd (SHILPA) Regulatory Update: Company has received final approval from SEC for marketing authorization of OERIS™ (Ondansetron Extended‑Release Injection, 100 mg/ml). This is the first extended‑release formulation providing antiemetic action for up to 120 hours, with plans for commercial launch in India. 📊 Key Highlights Product: OERIS™ (Ondansetron ER Injection, 100 mg/ml) Indication: Antiemetic therapy (prevents nausea/vomiting) Duration: Up to 120 hours extended release Approval: SEC marketing authorization Launch: Planned in India 📌 SWOT Analysis Strengths First‑in‑class extended‑release antiemetic in India. Strong R&D capabilities in oncology and supportive care. Regulatory approval enhances credibility. Weaknesses Dependence on oncology supportive care segment. Pricing pressures in Indian generics market. Opportunities Rising demand for antiemetic therapies in chemotherapy. Potential for global expansion of OERIS™. Strengthened specialty portfolio in injectables. Threats Competition from multinational pharma players. Regulatory hurdles in export markets. Risk of generic substitutes impacting margins. 🏭 Fundamentals Snapshot (FY26) Revenue: ~₹1,850 crore EBITDA Margin: ~18% PAT: ~210 crore Debt-to-Equity: ~0.4 Capex Plan: Focused on oncology APIs and formulations

See More

Shilpa Medicare Gets SEC Nod for OERIS™ Launch in India

Shilpa Medicare Ltd (SHILPA) Regulatory Update: Company has received final approval from SEC for marketing authorization of OERIS™ (Ondansetron Extended‑Release Injection, 100 mg/ml). This is the first extended‑release formulation providing antiemetic action for up to 120 hours, with plans for commercial launch in India. 📊 Key Highlights Product: OERIS™ (Ondansetron ER Injection, 100 mg/ml) Indication: Antiemetic therapy (prevents nausea/vomiting) Duration: Up to 120 hours extended release Approval: SEC marketing authorization Launch: Planned in India 📌 SWOT Analysis Strengths First‑in‑class extended‑release antiemetic in India. Strong R&D capabilities in oncology and supportive care. Regulatory approval enhances credibility. Weaknesses Dependence on oncology supportive care segment. Pricing pressures in Indian generics market. Opportunities Rising demand for antiemetic therapies in chemotherapy. Potential for global expansion of OERIS™. Strengthened specialty portfolio in injectables. Threats Competition from multinational pharma players. Regulatory hurdles in export markets. Risk of generic substitutes impacting margins. 🏭 Fundamentals Snapshot (FY26) Revenue: ~₹1,850 crore EBITDA Margin: ~18% PAT: ~210 crore Debt-to-Equity: ~0.4 Capex Plan: Focused on oncology APIs and formulations 📊 Key Ratios (FY26) Metric Value ROE ~12% ROCE ~13% Debt-to-Equity ~0.4 P/E Ratio ~19x

See More